Literature DB >> 8978443

The use of MRI in monitoring the treatment of multiple sclerosis.

D H Miller.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8978443     DOI： 10.1007/bf01997711

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


× No keyword cloud information.
  5 in total

1.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

Authors:  D H Miller; P S Albert; F Barkhof; G Francis; J A Frank; S Hodgkinson; F D Lublin; D W Paty; S C Reingold; J Simon
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

Review 2.  Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis.

Authors:  M Filippi; M A Horsfield; P S Tofts; F Barkhof; A J Thompson; D H Miller
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

3.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

4.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

5.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.